Search

Your search keyword '"H. Bayramoglu"' showing total 2 results
Start Over Author "H. Bayramoglu" Topic biomarkers, tumor
2 results on '"H. Bayramoglu"'

1. Inhibin alpha and beta expression in ovarian stromal tumors and their histological equivalences.

Author

Ciriş M, Erhan Y, Zekioglu O, and Bayramoglu H

Subjects
Case-Control Studies, Female, Humans, Immunohistochemistry, Predictive Value of Tests, Biomarkers, Tumor metabolism, Endometrial Stromal Tumors metabolism, Inhibin-beta Subunits metabolism, Inhibins metabolism, Ovarian Neoplasms metabolism
Abstract

Inhibin is a heterodimeric protein hormone that appears to be a sensitive immunohistochemical marker of sex cord-stromal tumors. Although sex cord-stromal tumors can usually be distinguished from ovarian epithelial tumors or their metastases by morphology or by using antibodies against intermediate filaments, the diagnosis remains difficult in rare situations in such cases as sarcomatoid granulosa-theca cell tumors, ovarian small cell carcinomas, or soft-tissue sarcomas. The purposes of this study were to examine inhibin alpha and beta immunoreactivity in a wide range of gonadal stromal neoplasms and to assess its value in the differential diagnosis of problematic tumors. A total of 108 paraffin-embedded ovarian and extraovarian tumors were examined immunohistochemically by using anti-alpha inhibin and anti-beta inhibin. Inhibin alpha immunostaining was identified in 46 (81%) of 57 gonadal stromal tumors, one (14%) of seven endometrial stromal tumors, and one (50%) of two primary ovarian carcinoid tumors. Inhibin beta immunostaining was detected in 55 (96%) of 57 gonadal stromal tumors, two (29%) of seven endometrial stromal tumors, one (50%) of two dysgerminomas, and in all of two (100%) primary ovarian carcinoid tumors. Inhibin alpha expression was not detected in any ovarian surface epithelial tumor cells. Some surface epithelial tumors showed stromal inhibin alpha (15% of cases) and inhibin beta (48% of cases) positivity. Weak immunoreactivity for inhibin beta was found in most (83% of cases) ovarian surface epithelial tumors. Two ovarian Burkitt lymphomas were negative for inhibin alpha and beta. Inhibin alpha is a sensitive immunohistochemical marker of gonadal stromal tumors and is of value in the differential diagnosis of ovarian neoplasia. Inhibin beta is a nonspecific marker for ovarian neoplasms, showing expression on tumor and stromal cells of different epithelial or stromal tumors.

Published
2004
Full Text
View/download PDF

2. Invasive micropapillary carcinoma of the breast: high incidence of lymph node metastasis with extranodal extension and its immunohistochemical profile compared with invasive ductal carcinoma

Author

Yildiz Erhan, H Bayramoglu, Osman Zekioglu, Metin Ciris, and Necmettin Özdemir

Subjects
Pathology, medicine.medical_specialty, Histology, Lymphovascular invasion, Breast surgery, medicine.medical_treatment, Mammary gland, Breast Neoplasms, Pathology and Forensic Medicine, Immunoenzyme Techniques, Breast cancer, Biomarkers, Tumor, medicine, Carcinoma, Humans, Lymph node, Aged, Retrospective Studies, business.industry, Carcinoma, Ductal, Breast, General Medicine, Middle Aged, Ductal carcinoma, medicine.disease, Carcinoma, Papillary, Treatment Outcome, medicine.anatomical_structure, Receptors, Estrogen, Lymphatic Metastasis, Female, Lymph Nodes, Lymph, Neoplasm Recurrence, Local, Receptors, Progesterone, business
Abstract

Aims : Invasive micropapillary carcinoma of the breast is an aggressive and distinctive variant of breast cancer. These tumours have a characteristic histological appearance and have been associated with a high incidence of axillary lymph node metastases and a poor clinical outcome. The aims of this study were to investigate the immunohistochemical profile of invasive micropapillary carcinoma of the breast, to compare it with invasive ductal carcinoma, and to identify the morphological parameters which predict its poor outcome. Methods and results : Fifty-three (2.6%) invasive micropapillary carcinomas of the breast from 2022 cases of infiltrating breast carcinomas were identified by retrospective review. The patient age at presentation ranged from 33 to 78 years (mean 52.5 years). The tumour size ranged from 5 to 70 mm (mean 27 mm). Eighty-two percent (43 of 53) were of high histological grade; 69% (33 of 48) of cases with axillary lymph node dissections had positive lymph nodes; and 75.5% (40 of 53) had lymphatic invasion: 46% (22 of 48) of cases had extranodal extension. Of lymph node-positive cases, 61% had four or more metastatic lymph nodes. Of tumours with tumour size >10 mm, 77% had positive lymph nodes. The percentages of cases positive for oestrogen receptor (ER) and progesterone receptor (PR) were 68% and 61%, respectively. These values were significantly higher than the values for invasive ductal carcinomas. p53 and c-erbB-2 were detected in 48% and 54% of cases, respectively. The mean value of Ki67 was 26%. Follow-up was available in 36 patients. Eight patients had local recurrences, nine patients had distant metastases, and 10 patients died of disease within a follow-up period of 9 years. Conclusion : Lymphotropism and an unfavourable prognosis are the hallmarks of this distinct entity. Prognostic markers such as ER, PR, p53, and c-erbB-2 failed to provide new criteria to allow discrimination of these tumours from other breast cancers.

Published
2004
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results